A New Era in the Ethics of Human Embryonic Stem Cell Research

Authors

  • Bernard Lo M.D.,

    Corresponding author
    1. Program in Medical Ethics and Division of General Internal Medicine, San Francisco, California, USA
    • Room C 126, 521 Parnassus Avenue, San Francisco, California 94143-0903, USA. Telephone: 415-476-5370; Fax: 415-476-5020
    Search for more papers by this author
  • Patricia Zettler,

    1. Program in Medical Ethics and Division of General Internal Medicine, San Francisco, California, USA
    Search for more papers by this author
  • Marcelle I. Cedars,

    1. Department of Medicine and Department of Obstetrics, Gynecology, and Reproductive Sciences, San Francisco, California, USA
    Search for more papers by this author
  • Elena Gates,

    1. Department of Medicine and Department of Obstetrics, Gynecology, and Reproductive Sciences, San Francisco, California, USA
    Search for more papers by this author
  • Arnold R. Kriegstein,

    1. Program in Development and Stem Cell Biology and Department of Neurology at the University of California San Francisco, San Francisco, California, USA
    Search for more papers by this author
  • Michelle Oberman,

    1. School of Law at Santa Clara University, Santa Clara, California, USA
    Search for more papers by this author
  • Renee Reijo Pera,

    1. Department of Medicine and Department of Obstetrics, Gynecology, and Reproductive Sciences, San Francisco, California, USA
    2. Program in Human Embryonic Stem Cell Biology, San Francisco, California, USA
    Search for more papers by this author
  • Richard M. Wagner,

    1. Human Subjects Protection Program, San Francisco, California, USA
    Search for more papers by this author
  • Mary T. Wuerth,

    1. Community member of the UCSF Committee on Gamete, Embryo, and Stem Cell Research, San Francisco, California, USA
    Search for more papers by this author
  • Leslie E. Wolf,

    1. Program in Medical Ethics and Division of General Internal Medicine, San Francisco, California, USA
    Search for more papers by this author
  • Keith R. Yamamoto

    Corresponding author
    1. Department of Cellular and Molecular Pharmacology at the University of California San Francisco, San Francisco, California, USA
    • Room C 126, 521 Parnassus Avenue, San Francisco, California 94143-0903, USA. Telephone: 415-476-5370; Fax: 415-476-5020
    Search for more papers by this author

Abstract

Scientific progress in human embryonic stem cell (hESC) research and increased funding make it imperative to look ahead to the ethical issues generated by the expected use of hESCs for transplantation. Several issues should be addressed now, even though phase I clinical trials of hESC transplantation are still in the future. To minimize the risk of hESC transplantation, donors of materials used to derive hESC lines will need to be recontacted to update their medical history and screening. Because of privacy concerns, such recontact needs to be discussed and agreed to at the time of donation, before new hESC lines are derived. Informed consent for phase I clinical trials of hESC transplantation also raises ethical concerns. In previous phase I trials of highly innovative interventions, allegations that trial participants had not really understood the risk and benefits caused delays in subsequent trials. Thus, researchers should consider what information needs to be discussed during the consent process for hESC clinical trials and how to verify that participants have a realistic understanding of the study. Lack of attention to the special ethical concerns raised by clinical trials of hESC transplantation and their implications for the derivation of new hESC lines may undermine or delay progress toward stem cell therapies.

Ancillary